Skip to main content
Premium Trial:

Request an Annual Quote

Nanogen to Develop Diagnostic Chips with Philadelphia Children s Hospital

NEW YORK, Oct. 31 - Children’s Hospital of Philadelphia has purchased Nanogen’s NanoChip technology to under a special collaborative research agreement to develop clinical diagnostic assays for childhood genetic diseases, Nanogen said Tuesday.


Under the terms of the deal, Children's Hospital will provide laboratory resources, collaborative expertise, and product revenue in exchange for non-exclusive access to Nanogen's electronic DNA microarrays.


Nanogen and Children's Hospital have also agreed to publish and present the validated study results.


“The agreement with Children's Hospital broadens our development efforts by applying the NanoChip technology to the most challenging areas of genetic testing, clearly differentiating our product from other systems," Nanogen CEO Howard Birndorf said in a statement.


This is the first collaboration announced under Nanogen's Development Site Program. Nanogen has also entered into collaborative chip development agreements with the US Army and the Defense Advanced Research Projects Agency and has sold its chips to the National Cancer Institute, the Mayo Clinic, and Aventis.

The Scan

Should've Been Spotted Sooner

Scientists tell the Guardian that SARS-CoV-2 testing issues at a UK lab should have been noticed earlier.

For Martian Fuel

Researchers have outlined a plan to produce rocket fuel on Mars that uses a combination of sunlight, carbon dioxide, frozen water, cyanobacteria, and engineered E. coli, according to Gizmodo.

To Boost Rapid Testing

The Washington Post writes that new US programs aim to boost the availability of rapid at-home SARS-CoV-2 tests.

PNAS Papers on Strawberry Evolution, Cell Cycle Regulators, False-Positive Triplex Gene Editing

In PNAS this week: strawberry pan-genome, cell cycle-related roles for MDM2 and MDMX, and more.